Results of the PROMINENT trial added a new wrinkle to the stories of fibrates and triglyceride-lowering in cardiovascular risk management, with the randomized, double-blind, placebo-controlled trial finding a reduction in triglycerides with use of pemafibrate in a population with diabetes and hypertriglyceridemia was not associated with a reduced risk of adverse cardiovascular outcomes.
Presented at the American Heart Association 2022 Scientific Sessions by Aruna Pradhan, MD, MPH, results of the trial, which also found pemafibrate use associated with an increased incidence of adverse renal events and venous thromboembolism, add clarity to the understanding of use of the fibrate class of medications in statin-treated patients, but a twist in the story of the observed risk reduction achieved with use of icosapent ethyl and EPA in other trials, including RESPECT-EPA, which was also presented at AHA 2022.
To learn more about PROMINENT and how it helps to inform care, hosts of The Heart Team, Jorge Plutzky, MD, director of preventive cardiology at Brigham and Women’s Hospital, and Michael Farkouh, MD, Peter Munk Chair in Multinational Clinical Trials at the Peter Munk Cardiac Centre, sat down with Pradhan following her presentation at AHA 2022. In the episode, Pradhan, an associate professor of medicine at Harvard Medical School, discusses the design, results, and her interpretation of the PROMINENT trial for practicing clinicians. Later in the episode, Pradhan discusses the current knowledge base surrounding triglycerides and cardiovascular risk as well as how she interprets use of triglyceride-lowering agents in the wake of PROMINENT and RESPECT-EPA results.